Researchers from Denmark have uncovered strong evidence that depression often appears years before Parkinson’s disease and ...
Exploring withdrawal risks, symptom variability, and safer discontinuation strategies Many people are surprised by how ...
Migraine Again on MSN
Migraine and depression: How to manage both conditions at the same time
About 80 per cent of people with migraine experience depression. Learn about common symptoms and options for treating both ...
Bunnie XO shares her harrowing experience with an experimental weight-loss drug, describing severe depression and suicidal ...
A major Australian study finds standard antidepressants are not effective for around 20 per cent of people, who may need ...
Steven Stoner, PharmD, advises managed care teams to use rigorous diagnostic assessments, monitor adherence, and invest ...
PsyPost on MSN
Scientists reveal atypical depression is a distinct biological subtype linked to antidepressant resistance
A new genetic and clinical analysis suggests that atypical depression represents a distinct biological subtype of the ...
His much-acclaimed novel, titled “old man and the sea,” in my view is well connected to moods, words, and deeds. As his last ...
Inside a wellness spa in Chicago’s River North neighborhood, a video of Gwyneth Paltrow plays on a quiet loop near the ...
Clinical Trials Arena on MSN
Axsome begins Phase III AXS-14 FORWARD trial for fibromyalgia management
The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.
The AACE has updated its guidance on obesity and adiposity-based chronic disease to reflect a focus on improving overall ...
DENVER, CO / / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results